GlobeStar Therapeutics Corp (GSTC)

[Aquahoya]

$GSTC Globestar History

What is Globestar Therapeutics?

Formerly known as Angiosoma ($SOAN), formerly run by Alex Blankenship. In April 2020, Alex Blankenship was able to secure U.S. patent 10,610,592, a patent developed by Fabrizio De Silvestri (company is 7 to Stand, Inc) from Terni, Italy. https://www.otcmarkets.com/filing/html?id=14747280&guid=xsG-kKvkPiDadth

In December 2020, Blankenship sought a firm that had history with bringing drugs to market, and in March 3, 2021, the board appoints Jim Katzaroff as CEO of both the subsidiary company (Somaceuticals), and parent company (Angiosoma). https://www.otcmarkets.com/filing/html?id=14777626&guid=xsG-kKvkPiDadth.

In August/September Angiosoma changed to Globestar Therapeutics, Inc. Globestar is a clinical stage pharmaceutical company testing a worldwide patented formulation of 3 drugs previously approved by the FDA. Pre-clinical trials in Italy showed the drug combination was effective in the reduction of MS co-morbidities. GlobeStar is initiating discussions with the FDA on clinical trial design in the U.S. in preparation for FDA submission and approval. https://www.otcmarkets.com/stock/GSTC/profile

What is patent 10,610,592 therapy?

The patent specified a combinational tri-drug therapy that harnesses:

1. Minocycline - An oral tetracycline antibiotic. It's used to treat bacterial infections including respiratory and urinary tract infections.
2. Fluconazole - An triazole antifungal. Used to prevent and treat a variety of fungal and yeast infections by stopping the growth of CERTAIN types of fungus (candida albicans).
3. Atorvastatin - A statin HMG CoA reductase inhibitor. Commonly used to lower blood levels of LDL cholesterol, increase levels of HDL cholesterol and to lower triglycerides. It's also an effective immunomodulatory agent shown to prevent autoimmune encephalomyelitis in animal model studies.
https://www.otcmarkets.com/filing/html?id=15232865&guid=xsG-kKvkPiDadth

Multiple Sclerosis affects roughly 2,300,000 million people a year costing roughly $70,000 yearly. This therapy would dramatically drop costs.

Who is on the Globestar Therapeutics, Inc team?



Bill Farley - https://www.otcmarkets.com/filing/html?id=14875624&guid=xsG-kKvkPiDadth
Brooke Greenwald - https://www.otcmarkets.com/filing/html?id=14933181&guid=xsG-kKvkPiDadth
Steven F. Penderghast
David Croom
Dr. Leonard Wisneski, MD, FACP

Subsequently, Kenin Spivak was also brought in as a consultant in April 2022 (https://www.imdb.com/name/nm1221859/bio). https://www.otcmarkets.com/filing/html?id=15725607&guid=xsG-kKvkPiDadth

Was there an initial clinical study?


Yes. The initial study consisted of 150 volunteers, 90 subjects ages (25-65) with MS between 5-20 years (including 60 control volunteers). They used Barthel Index (used as a mobility disability index). They also used a scale for muscle imbalance (Kendall Scale), before and after treatment.

The subjects received 2 doses/day for 45 days, along with a controlled diet.





Fabrizio de Silvestri (https://patents.justia.com/inventor/fabrizio-de-silvestri) is a lawyer by trade (1998), but suffers, himself, from Multiple Sclerosis. In 2005, he started studying forensic medicine. He researched to try to find a better therapy filing the patent in 2015 (Applied in 2014). In regard to speaking about the therapy itself, he said,

My patented formula is a composition for treating neurodegeneration, including an antibiotic, an antifungal agent, and a lipophilic potentiating agent in synergistically effective amounts.

Has the team developed North American/World Projections?





Has James Katzaroff tried approaching hospitals?

In October 4, 2021, Leonard Wisnecki, MD met with Merit Cudkowitz, M.D., Chief of Neurology, Mass General Hospital, on July 19, 2021. This fell through but he had talks with numerous other hospital including Cedar Sinai, Stanford, and numerous others that allude me.

Since then, we have been waiting patiently for Jim to make the magic happen. They secured financing with New York Bay Capital which was in the tune of $19-21,000,000 from anecdotal calls with Jim. Which one would expect with clinical trials.

In April/May, Jim appeared on the Emerging Growth Conference to provide some updates to the shareholders. Not much was provided other than looking for a hospital. In November 10, 2022, Jim updated the shareholders that he was deep in discussions with Apollo Hospitals. An international hospital company with revenues in the billions and a staffing in the 10s of the thousands.